Reingold A L, Broome C V, Hightower A W, Ajello G W, Bolan G A, Adamsbaum C, Jones E E, Phillips C, Tiendrebeogo H, Yada A
Lancet. 1985 Jul 20;2(8447):114-8. doi: 10.1016/s0140-6736(85)90224-7.
Sequential case-control studies were used to monitor changes in the clinical protection induced by group A meningococcal polysaccharide vaccine over a 3-year period. Overall, vaccine efficacy declined from 87% 1 year after vaccination to 70% and 54% at 2 and 3 years, respectively. When stratified by age at time of vaccination the data showed that, although vaccine efficacy remained high in children greater than or equal to 4 years of age (vaccine efficacy 85%, 74%, and 67% at 1, 2, and 3 years after vaccination, respectively), it declined dramatically in those less than 4 years of age at time of vaccination (vaccine efficacy 100%, 52%, and 8%, respectively, at 1, 2, and 3 years after vaccination). Thus, a single dose of group A meningococcal vaccine does not yield lasting clinical protection in children less than 4 years of age.
采用序贯病例对照研究来监测A群脑膜炎球菌多糖疫苗在3年期间所诱导的临床保护作用的变化。总体而言，疫苗效力在接种后1年时从87%降至2年和3年时的70%和54%。按接种时年龄分层的数据显示，尽管4岁及以上儿童的疫苗效力仍保持较高水平（接种后1年、2年和3年时的疫苗效力分别为85%、74%和67%），但接种时年龄小于4岁的儿童的疫苗效力显著下降（接种后1年、2年和3年时的疫苗效力分别为100%、52%和8%）。因此，单剂A群脑膜炎球菌疫苗不能为4岁以下儿童提供持久的临床保护。
